Rocket Pharma (RCKT)
NASDAQ:RCKT
Want to see RCKT full AI Analyst Report?
Top Page
Rocket Pharmaceuticals
(NASDAQ:RCKT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▼(-23.27% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by weak financial performance (no revenue, large losses, and substantial cash burn) and bearish technicals (below key moving averages with negative MACD). These are partially offset by major positive corporate catalysts—FDA approval and $180M in non-dilutive proceeds that extend the cash runway—while valuation is difficult to assess due to negative earnings and no dividend data.
Positive Factors
Regulatory approval (KRESLADI)
Accelerated FDA approval is a durable validation of Rocket's science and regulatory capabilities. It converts years of R&D into a de-risking milestone, enabling commercialization pathways, generating regulatory assets (PRV), and strengthening credibility for partners and payors over the next several years.
Negative Factors
No revenue and large losses
The company remains pre-commercial with no product-driven revenue and very large trailing losses. Persistently negative profitability means value depends on future approvals and commercialization; absent durable revenues, ongoing losses will continue to erode capital and investor optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approval (KRESLADI)
Accelerated FDA approval is a durable validation of Rocket's science and regulatory capabilities. It converts years of R&D into a de-risking milestone, enabling commercialization pathways, generating regulatory assets (PRV), and strengthening credibility for partners and payors over the next several years.
Read all positive factors
Rocket Pharmaceuticals (RCKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$365.80M
Dividend YieldN/A
Average Volume (3M)2.52M
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth28.56%
CountryUS
Employees299
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding109,193,550
10 Day Avg. Volume2,641,941
30 Day Avg. Volume2,519,803
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.41
Price to Sales (P/S)0.00
P/FCF Ratio-2.05
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.35
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$9.75Price Target Upside149.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$2.29M
Rocket Pharmaceuticals Business Overview & Revenue Model
Company Description
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multipl...
How the Company Makes Money
null...
Rocket Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.68M | -11.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -194.47M | -210.21M | -247.49M | -236.62M | -213.69M | -157.81M |
| Net Income | -209.38M | -223.12M | -258.75M | -245.59M | -221.86M | -169.07M |
Balance Sheet | ||||||
| Total Assets | 285.41M | 330.45M | 527.70M | 566.34M | 551.81M | 497.02M |
| Cash, Cash Equivalents and Short-Term Investments | 144.38M | 188.93M | 372.34M | 373.18M | 356.39M | 388.74M |
| Total Debt | 24.76M | 24.88M | 25.50M | 25.04M | 22.87M | 22.60M |
| Total Liabilities | 47.37M | 53.23M | 64.47M | 73.77M | 62.12M | 42.30M |
| Stockholders Equity | 238.04M | 277.22M | 463.23M | 492.57M | 489.69M | 454.72M |
Cash Flow | ||||||
| Free Cash Flow | -179.79M | -190.45M | -215.59M | -211.39M | -186.76M | -128.88M |
| Operating Cash Flow | -179.63M | -190.01M | -209.72M | -194.92M | -178.14M | -121.16M |
| Investing Cash Flow | 179.25M | 103.77M | 131.71M | -98.07M | -69.33M | 18.85M |
| Financing Cash Flow | 155.00K | 148.00K | 185.74M | 208.40M | 155.29M | 37.68M |
Rocket Pharmaceuticals Technical Analysis
Positive
3.91
Price Trends
3.30
Positive
3.66
Negative
3.54
Negative
Market Momentum
-0.09
Negative
60.94
Neutral
78.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCKT, the sentiment is Positive. The current price of 3.91 is above the 20-day moving average (MA) of 2.91, above the 50-day MA of 3.30, and above the 200-day MA of 3.54, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 60.94 is Neutral, neither overbought nor oversold. The STOCH value of 78.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RCKT.
Rocket Pharmaceuticals Risk Analysis
Rocket Pharmaceuticals disclosed 3 risk factors in its most recent earnings report. Rocket Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our strategic restructuring may not result in the savings we anticipate, could result in total costs and expenses that are greater than expected and could disrupt our operations Q2, 2025
2.
We are and may continue to be targets of securities-related class action and derivative lawsuits and defending against these claims could result in substantial costs and divert management time and resources and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, may be costly to defend or pursue and are uncertain in their outcome Q2, 2025
Rocket Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $401.90M | -1.39 | -128.53% | ― | 928.46% | -21.39% | |
52 Neutral | $504.99M | -4.09 | -36.83% | ― | 383560.87% | 20.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $365.80M | -1.79 | -70.79% | ― | ― | 28.56% | |
50 Neutral | $860.74M | -15.43 | -73.23% | ― | ― | -42.64% | |
49 Neutral | $642.22M | -8.84 | -36.61% | ― | -75.91% | -173.33% | |
45 Neutral | $484.33M | -64.71 | -4.21% | ― | 121.11% | 80.74% |
* Healthcare Sector Average
RCKT
Rocket Pharmaceuticals
3.35
0.65
24.07%
ASMB
Assembly Biosciences
24.44
7.05
40.54%
CTMX
CytomX Therapeutics
2.95
0.63
27.16%
AUTL
Autolus Therapeutics
1.51
-0.54
-26.34%
FDMT
4D Molecular Therapeutics
9.66
5.53
133.90%
DRTS
Alpha Tau Medical Ltd
9.78
6.88
237.24%
Rocket Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
Positive
Jun 12, 2026
On June 10, 2026, Rocket Pharmaceuticals completed the sale of its FDA-issued Rare Pediatric Disease Priority Review Voucher, originally granted with the approval of its gene therapy KRESLADI for severe leukocyte adhesion deficiency-I, to a large ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
Positive
May 21, 2026
Rocket Pharmaceuticals held its 2026 Annual Meeting of Stockholders on May 20, 2026, with approximately 74% of eligible common shares represented in person or by proxy. Stockholders elected seven directors to the board, including Gaurav Shah, M.D....
Business Operations and StrategyPrivate Placements and Financing
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
Positive
Apr 28, 2026
On April 26, 2026, Rocket Pharmaceuticals entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher that it was awarded after the U.S. Food and Drug Administration granted accelerated approval to its gene therapy...
Business Operations and StrategyProduct-Related Announcements
Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
Positive
Mar 27, 2026
On March 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration granted accelerated approval to KRESLADI, an autologous hematopoietic stem cell-based gene therapy for pediatric patients with severe leukocyte adhesion...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.